Please use this identifier to cite or link to this item:
http://repositorio.unicamp.br/jspui/handle/REPOSIP/353568
Type: | Outro documento |
Title: | Erratum to “Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia” |
Author: | Rodrigues, C.A. Gonçalves, M.V. Ikoma, M.R.V. Lorand-Metze, I. Pereira, A.D. Farias, D.L.C.D. Chauffaille, M.D.L.L.F. Schaffel, R. Ribeiro, E.F.O. Rocha, T.S.D. Buccheri, V. Vasconcelos, Y. Figueiredo, V.L.D.P. Chiattone, C.S. Yamamoto, M. Brazilian Group of Chronic Lymphocytic Leukemia |
Abstract: | In the article “Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia”, published in Rev Bras Hematol Hemoter 2016;38:346–57, please consider the following correction: 2) Relapsed first-line treatment: a) Progress after 24 months: repeat first-line treatment (add an anti-CD20 antibody if not used in the first-line treatment)b) Progress within 24 months: - ‘Go-go’ patients: ibrutinib • Alternative options: venetoclax, alemtuzumab with or without methylprednisolone, rituximab with or without high-dose methylprednisolone, allogeneic HCST, bendamustine plus rituximab- ‘Slow-go’ patients: ibrutinib • Alternative options: idelalisib plus rituximab, alemtuzumab with or without methylprednisolone, rituximab with or without high-dose methylprednisolone bendamustine plus rituximab, FCR-lite © 2016 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular |
Subject: | Leucemia |
Country: | Brasil |
Editor: | Associação Brasileira de Hematologia e Hemoterapia |
Rights: | Aberto |
Identifier DOI: | 10.1016/j.bjhh.2017.01.002 |
Address: | https://www.sciencedirect.com/science/article/pii/S1516848417300075 |
Date Issue: | 2017 |
Appears in Collections: | FCM - Artigos e Outros Documentos |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.